OOIR: Observatory of International Research

Papers

(The median citation count of Lancet Haematology is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)

Article	Citations
Towards reparatory measures: blood donation, health systems, and men who have sex with men	230
Another quadruplet therapy for multiple myeloma: the beginning of the end for autologous haematopoietic stem-cell transplantation?	214
In the trenches	182
Zanubrutinib-associated ecchymotic lesions	178
“I can't breathe”: how sickle cell disease manifests in the USA today	167
Prioritising health equity alongside donation safety – Authors' reply	148
Trials and tribulations: including women in cancer clinical research	142
Will the changing therapeutic landscape meet the needs of patients with sickle cell disease?	138
Monoclonal B-cell lymphocytosis, monoclonal gammopathy of undetermined significance, and T-cell clones of uncertain significance: are these premalignant conditions sharing a common identity?	132
Retinal haemorrhage as a complication of blastic plasmacytoid dendritic cell neoplasm	117
Correction to Lancet Haematol 2023; 10: e333–45	113
Correction to Lancet Haematol 2023; published online Aug 28. https://doi.org/10.1016/S2352-3026(23)00164-3	112
Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts	111
Correction to Lancet Haematol 2024; 11: e114–26	111
Managing haematological malignancies in pregnant women	100
MRD-guided treatment cessation in multiple myeloma	98
Alloimmunisation against red blood cells in sickle cell disease: transfusion challenges in high-income and low-income countries	97
Is there still a role for CNS prophylaxis in diffuse large B-cell lymphoma?	97
Vaccine efficacy and iron deficiency: an intertwined pair?	93
Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial	83
Be compliant or compromise?	82
International Society on Thrombosis and Haemostasis Congress 2023	82
The HemeOncBuddy app—a new tool to keep up with the clinical trial storm	81
Venetoclax with intensive chemotherapy in younger patients with acute myeloid leukaemia	81
Bedside art is good medicine	80

Artwork from trauma: the social life of medical data	79
Sequencing therapies in Hodgkin lymphoma	73
CAR T cells in CNS-relapsed leukaemia: one step forward	70
Blinatumomab plus hyper-CVAD: the prelude to a new era in acute lymphocytic leukaemia	68
Using immunotherapy and novel trial designs to optimise front-line therapy in adult acute lymphoblastic leukaemia: breaking with the traditions of the past	66
Avatrombopag for chemotherapy-induced thrombocytopenia in patients with non-haematological malignancies: an international, randomised, double-blind, placebo-controlled, phase 3 trial	66
Polatuzumab vedotin plus rituximab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study	66
Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study	66
COVID-19 vaccines for patients with haematological conditions	65
Variations in antenatal management and outcomes in haemolytic disease of the fetus and newborn: an international, retrospective, observational cohort study	65
Racial and ethnic survival disparities in patients with haematological malignancies in the USA: time to stop ignoring the numbers	62
Tisagenlecleucel therapy for relapsed or refractory B-cell acute lymphoblastic leukaemia in infants and children younger than 3 years of age at screening: an international, multicentre, retrospective	62
Blood deserts: a vision to tackle blood inaccessibility	61
Blood cell defence against pathogens	58
Living with sickle cell disease: voices from sub-Saharan Africa	58
25 mm Hg versus 35 mm Hg elastic compression stockings to prevent post-thrombotic syndrome after deep vein thrombosis (CELEST): a randomised, double-blind, non-inferiority trial	57
Correction to Lancet Haematol 2023; 10: e433–44	56
Correction to Lancet Haematol 2021; 8: e205–15	54
Eltrombopag–cyclosporin A in treating severe aplastic anaemia	54
Call to action: equitable comprehensive care for patients with sickle cell disease in the USA	54
Production and supply of blood products in Brazil	54
Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations	53
Sickle cell disease in India: current status and progress	53
Rituximab versus active surveillance in patients with follicular lymphoma	52
Epidemiology, clinical features, and outcomes of peripheral T-cell lymphoma in Latin America: an international, retrospective, cohort study	50
Methodological challenges in the development of endpoints for myelofibrosis clinical trials	50
Update on SickleInAfrica: a collaborative and multidimensional approach to conduct research and improve health	50
Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, ran	48
Idiopathic multicentric Castleman disease with arteriolar endotheliopathy and secondary haemophagocytosis	47
Universal health coverage for children with cancer	46
Could improving mental health disorders help increase cancer survival?	46
Maintaining the minimal: dynamics of measurable residual disease with continuous lenalidomide therapy	46
[18F]FDG-PET-CT compared with CT for persistent or recurrent neutropenic fever in high-risk patients (PIPPIN): a multicentre, open-label, phase 3, randomised, controlled trial	45
Global effort to evacuate Ukrainian children with cancer and blood disorders who have been affected by war	45
Early switch to oral anticoagulation in patients with acute intermediate-risk pulmonary embolism (PEITHO-2): a multinational, multicentre, single-arm, phase 4 trial	44
Progressive multifocal leukoencephalopathy in the era of chimeric antigen receptor T-cell therapy	44
Correction to Lancet Haematol 2022; Published online July 27. https://doi.org/10.1016/S2352-3026(22)00206-X	43
Correction to Lancet Haematol 2024; 11: e310–11	43
Vodobatinib for patients with Philadelphia chromosome-positive chronic myeloid leukaemia resistant or intolerant to multiple lines of previous therapy: an open-label, multicentre, phase 1/2 trial	42
Targeting CD70 in acute myeloid leukaemia: an emerging therapeutic angle in combinatorial treatment	42
Oreofe Odejide—aiming to raise the bar in haematology care	42
Correction to Lancet Haematol 2022; 9: e200–07	42
Vacuoles in bone marrow progenitors: VEXAS syndrome and beyond	41
Hydroxyurea with dose escalation for primary stroke risk reduction in children with sickle cell anaemia in Tanzania (SPHERE): an open-label, phase 2 trial	41
Addressing inequity in access to palliative care for patients with non-malignant or benign haematological diseases	40
Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study	40
CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials	40
A long-awaited benchmark in lymphomatoid granulomatosis	39
Thank you to our 2022 peer reviewers and an update on inclusion and diversity	39
Sickle cell disease—unity and patient-centred education	39

Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-lab	39
Secondary haematological malignancies	38
The rollercoaster of vaccine-induced immune thrombotic thrombocytopenia	38
Reporting of trials with possible detrimental overall survival: a patient advocate perspective	37
Lakshmi Nayak: striving to contain the brain's deadliest killers	37
Should patients with haemophilia receive gene therapy?	36
Striking the right balance	36
Haemophilia—unparalleled progress but inadequate access	35
Haematology and climate change	35
Elotuzumab: no additional effect in patients with newly diagnosed multiple myeloma	35
Beyond remission: secondary primary malignancies in patients with lymphoma after autologous haematopoietic stem-cell transplantation	35
Survival and quality of life in patients with lower risk myelodysplastic syndromes exposed to erythropoiesis-stimulating agents: an observational cohort study	34
In-vivo T-cell depleted reduced-intensity conditioned allogeneic haematopoietic stem-cell transplantation for patients with acute lymphoblastic leukaemia in first remission: results from the prospecti	34
The challenge of defining the global burden of iron deficiency anaemia	34
2024 ASH Annual Meeting	34
Crizanlizumab with or without hydroxyurea in patients with sickle cell disease (STAND): primary analyses from a placebo-controlled, randomised, double-blind, phase 3 trial	33
Removing unfair barriers to blood donation	32
Life beyond blood disorders	32
Comparison of international guideline recommendations for the diagnosis of pulmonary embolism	32
Can defibrotide prophylaxis prevent sinusoidal obstruction syndrome following haematopoietic stem-cell transplantation?	32
Immune effector cell-associated haematotoxicity after CAR T-cell therapy: from mechanism to management	32
In defence of individualised medicine	31
Gene therapy in China: past, present, and future	31
Accurate accounting of caplacizumab cost effectiveness – Authors' reply	31
Thank you to The Lancet Haematology's peer reviewers in 2022	31
The case for equitable haemophilia care	30
The Lancet Haematology at 10	30
The impact of patient ethnicity on haematopoietic cell transplantation outcome: a retrospective cohort study on the UK experience	29
Correction to Lancet Haematol 2021; 8: e185–93	28
Anti-BCMA/GPRC5D bispecific CAR T cells for relapsed or refractory multiple myeloma: is 1 + 1 greater than 2?	28
Sovleplenib in immune thrombocytopenia	27
Sovleplenib (HMPL-523), a novel Syk inhibitor, for patients with primary immune thrombocytopenia in China: a randomised, double-blind, placebo-controlled, phase 1b/2 study	27
Haematopoietic stem-cell transplantation in older adults: geriatric assessment, donor considerations, and optimisation of care	26
Management of pregnancies with anti-K alloantibodies and the predictive value of anti-K titration testing	26
Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial	26
Integrated molecular and immunological features of human T-lymphotropic virus type 1 infection and disease progression to adult T-cell leukaemia or lymphoma	25
Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow	25
Breaking sex biases: access for all in haemophilia care	25
Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group	25
A treatise on clinical trials	24
Acquired haemophilia in an Edo period Japanese surgical casebook	24
Artificial intelligence in peripheral blood films: an evolving landscape	24
Melflufen in multiple myeloma: the conclusion matters	24
Ask, do not tell: consulting a patient advisory board to understand unmet needs of patients with GVHD in Europe	24
A rare blood disorder that created a watercolour storytelling movement	23
Riociguat in patients with sickle cell disease and hypertension or proteinuria (STERIO-SCD): a randomised, double-blind, placebo controlled, phase 1–2 trial	23
Factor B inhibition for paroxysmal nocturnal haemoglobinuria	23
The effects of upward revision of haemoglobin thresholds for anaemia in blood donations	22
Clinical trial design change implementation for inclusive studies	22
Needles were the least of my worries	22
Don Thomas: leading the charge to bone marrow transplantation	22
Making a case for disease-modifying agents in myelofibrosis	22
Heavy menstrual blood loss in patients with von Willebrand disease: an unsolved problem	21
Iron deficiency anaemia in sub-Saharan Africa: a review of current evidence and primary care recommendations for high-risk groups	21
Patients receiving allogeneic haematopoietic stem-cell transplantation and clinical outcomes after early access to palliative care	21
Mental health disorders and survival among older patients with diffuse large B-cell lymphoma in the USA: a population-based study	21
UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation t	21
Monumen-TAL progress in the treatment of relapsed multiple myeloma	20
Optimising maintenance therapy after transplantation: sorafenib's role in patients with FLT3-ITD acute myeloid leukaemia	20
Emicizumab prophylaxis in patients with acquired haemophilia A (GTH-AHA-EMI): an open-label, single-arm, multicentre, phase 2 study	20
COVID-19 vaccination antibody responses in patients with aplastic anaemia and paroxysmal nocturnal haemoglobinuria	20
Incidence and prognosis of superficial vein thrombosis during pregnancy and the post-partum period: a Danish nationwide cohort study	20
Oleksandr Lysytsia: the war in Ukraine has changed everything about our lives	20
Making blood count	19
Reducing toxic waste: improving toxicity capture in childhood cancer	19
Mitapivat for treatment of pyruvate kinase deficiency	19
Lines of the haematology community	19
Regional empowerment through decentralised governance under a centralised regulatory system facilitates the development of cellular therapy in China	18
Epistemic limitations of measurable residual disease in haematological malignancies	18
Low-dose dasatinib: when less can be more	17
Effect of rituximab on immune status in children with mature B-cell non-Hodgkin lymphoma: a prespecified secondary analysis of the Inter-B-NHL Ritux 2010 trial	17
Antifibrinolytics do not add to the benefits of platelet transfusion	17
Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study	17
Immunochemotherapy for life-threatening haematological malignancies in pregnancy: a systematic review of the literature and cross-sectional analysis of clinical trial eligibility	16
Haematological malignancies in sub-Saharan Africa: east Africa as an example for improving care	16
Improved survival and enhanced quality of life through anaemia correction in lower risk myelodysplastic syndromes: meaningful insights from an EUMDS Registry study	16
Efficacy and safety of sovleplenib (HMPL-523) in adult patients with chronic primary immune thrombocytopenia in China (ESLIM-01): a randomised, double-blind, placebo-controlled, phase 3 study	16
Brentuximab vedotin with AVD for stage II–IV HIV-related Hodgkin lymphoma (AMC 085): phase 2 results from an open-label, single arm, multicentre phase 1/2 trial	16
CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose e	15
A comprehensive approach to therapy of haematological malignancies in older patients	15

Short versus extended treatment with a carbapenem in patients with high-risk fever of unknown origin during neutropenia: a non-inferiority, open-label, multicentre, randomised trial	15
The effects of revised haemoglobin cutoffs on the global burden of anaemia	15
Correction to Lancet Haematol 2021; 8: e55–66	14
Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial	14
Surviving the storm: critical care outcomes of chimeric antigen receptor T-cell therapy	14
Sevuparin for the treatment of acute pain crisis in patients with sickle cell disease: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial	14
Rosline Hassan: building the future of haemato-pathology in Malaysia	13
Long-term data from the REACH study testing hydroxyurea to treat sickle cell anaemia in children in sub-Saharan Africa	13
Time to define and refine maintenance strategies in acute myeloid leukaemia	13
Reactivating hope for TP53-mutated acute myeloid leukaemia?	13
Lallindra Gooneratne—maintaining treatment flow amid crisis	13
Long term strategies for individuals with sickle cell disease	13
Correction to Lancet Haematol 2024; 11: e862–72	13
Sexually transmitted infections in the context of haematological malignancies	12
Melflufen in multiple myeloma: the conclusion matters – Authors' reply	12
Conditioning regimens for HSCT for patients with high-risk myelodysplastic syndrome and secondary acute myeloid leukaemia	12
Haematology in sub-Saharan Africa: advances and opportunities in health care, education, and research	12
Correction to Lancet Haematol 2023; 10: e203–12	12
An integrated approach to cardioprotection in lymphomas	11
Public health and programme development in sickle cell disease in Ghana: the legacy of Kwaku Ohene-Frempong	11
Pembrolizumab and low-dose, single-fraction radiotherapy for patients with relapsed or refractory multiple myeloma: a prospective, single-centre, single-group, open-label, phase 2 pilot trial in the U	11
Treatment approaches for patients with TP53-mutated mantle cell lymphoma	11
Iron deficiency anaemia—an ongoing challenge	11
Haemoglobin thresholds to define anaemia from age 6 months to 65 years: estimates from international data sources	11
Rituximab biosimilars for B-cell lymphomas: a decade of real-world experience from India	11
The value of anti-CD30 CAR T cells in Hodgkin lymphoma	10
Under-recognition of measurement and management of serum ferritin among populations at high risk of iron deficiency – Authors' reply	10
Follicular lymphoma: is more better or is less really more?	10
Isolated IgG4-related disease of the left maxillary antrum	10
Correction to Lancet Haematol 2023; 10: e713–34	9
Renal colocalisation of Rosai-Dorfman-Destombes disease and secondary AA amyloidosis successfully treated with lenalidomide and dexamethasone	9
Sevuparin trial for acute pain in sickle cell disease: the dog that did not bark	9
Should patients with Ph-negative acute lymphoblastic leukaemia who reach minimal residual disease negativity have HSCT?	9
Is dose-adjusted EPOCH-R the new standard for high-risk Burkitt lymphoma?	9
Safe blood supply in sub-Saharan Africa: challenges and opportunities	9
Oncology service priorities for the new UK Government	9
Prehospital blood transfusion for haemorrhagic shock – Authors' reply	9
Virginia Abello Polo—a once-in-a-lifetime opportunity	9
Should patients with Ph-negative acute lymphoblastic leukaemia who reach minimal residual disease negativity have HSCT?	9
Under-recognition of measurement and management of serum ferritin among populations at high risk of iron deficiency	8
Risk stratified management approaches for smouldering multiple myeloma: clinical research becomes clinical practice	8
Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study	8
Correction to Lancet Haematol 2025; 12: e128–37	8
Inequalities in the career pathway for paediatric HSCT and cellular therapy physicians	8
Concerns on perioperative anaemia management in the FIT trial	8
Luspatercept for the treatment of anaemia in non-transfusion-dependent β-thalassaemia (BEYOND): a phase 2, randomised, double-blind, multicentre, placebo-controlled trial	8
Resuscitation with blood products in patients with trauma-related haemorrhagic shock receiving prehospital care (RePHILL): a multicentre, open-label, randomised, controlled, phase 3 trial	8
Mental health and psychological resilience in sickle cell disease	8
Iadademstat in combination with azacitidine in patients with newly diagnosed acute myeloid leukaemia (ALICE): an open-label, phase 2a dose-finding study	8
Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma	8
Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trial	8
Fitusiran prophylaxis in severe haemophilia without inhibitors	8
CAR T-cell therapies in China: rapid evolution and a bright future	7
The dystopia of enforced childbirth	7
Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomise	7
Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study	7
The role of conferences in tackling inequalities	7
Haematopoietic stem-cell transplantation for sickle cell disease in low-income and middle-income countries: the experience in India	7
Racial and ethnic disparities in childhood and young adult acute lymphocytic leukaemia: secondary analyses of eight Children's Oncology Group cohort trials	7
Antibody response after third BNT162b2 dose in recipients of allogeneic HSCT	7
Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial	7
A curious case of a neutrophilic horn	7
Defibrotide prophylaxis for prevention of sinusoidal obstruction syndrome	7
Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or Sézary syndrome: a multicentre, phase 1 study	7
Maintaining MOMENTUM in myelofibrosis	7
Overcoming the unmet need of Richter transformation: the use of pirtobrutinib	7
Expecting more: the case for incorporating fertility services into comprehensive sickle cell disease care	7
Balancing toxicity and effectiveness in older adults with B-cell acute lymphocytic leukaemia	7
48th Annual Meeting of the EBMT	7
Correction to Lancet Haematol 2024; 11: e510–20	7
Is it time to tailor treatment on the basis of minimal residual disease in multiple myeloma?	7
Correction to Lancet Haematol 2024; 11: e38–50	7
Environmental impact of haematology care—measurement and mitigation	7
Molecular diagnosis of primary CNS lymphoma in 2024 using MYD88Leu265Pro and IL-10	7
Cristóbal Frutos: confronting treatment barriers	7
Ending the burden of sickle cell disease in Africa	6
Haematological malignancies in pregnancy: time for accurate incidence data	6
Factors to consider when assessing the IDOCS study	6
Correction to Lancet Haematol 2024; 11: e459–70	6
Maternal and obstetric outcomes in women with pregnancy-associated haematological malignancies: an observational nationwide cohort study	6
Prioritising health equity alongside donation safety	6
Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase	6
Bleeding disorders: adapting to change	6
Fine-tuning the risk assessment and treatment of patients with intermediate-risk pulmonary embolism	6
Assessing authorship of clinical practice guidelines	6
CAR T-cell therapy: navigating real-world challenges beyond clinical trials	6
Global, regional, and national prevalence and mortality burden of sickle cell disease, 2000–2021: a systematic analysis from the Global Burden of Disease Study 2021	6
Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies	6
MGIP, MGUS, and the PROMISE of meaning in small things	6
Time to add gemtuzumab ozogamicin to intensive chemotherapy for NPM1-mutated acute myeloid leukaemia?	6
Ferric carboxymaltose infusion versus oral iron supplementation for preoperative iron deficiency anaemia in patients with colorectal cancer (FIT): a multicentre, open-label, randomised, controlled tri	6
CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre	6
Correction to Lancet Haematol 2021; 8: e711–22	5
Defibrotide plus best standard of care compared with best standard of care alone for the prevention of sinusoidal obstruction syndrome (HARMONY): a randomised, multicentre, phase 3 trial	5
Decitabine versus intensive chemotherapy induction for older patients with acute myeloid leukaemia: a futile but successful trial	5